![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Russia’s COVID-19 Vaccine Appears Promising in Early Trials
Russia’s COVID-19 Vaccine Appears Promising in Early Trials
![Russia on map with flag](https://www.fdanews.com/ext/resources/test/Device_Images6/RussiawithRussianFlag.gif?t=1616695725&width=430)
September 8, 2020
Russia’s COVID-19 vaccine was found to induce an immune response with no serious adverse events, according to data from two phase 1/2 trials.
The Sputnik V vaccine induced neutralizing antibodies in all participants and induced a strong T-cell response, according to the study report in The Lancet. The two trials enrolled a total of 76 participants who received different formulations of the vaccine.
Russia’s Ministry of Health granted conditional approval for the vaccine last month, making it the first COVID-19 vaccine approved in the world.
Upcoming Events
-
21Oct